首页 | 本学科首页   官方微博 | 高级检索  
     


Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer
Authors:Karen L. Reckamp MD  Marianna Koczywas MD  Mihaela C. Cristea MD  Jonathan E. Dowell MD  He‐Jing Wang PhD  Brian K. Gardner PhD  Ginger L. Milne PhD  Robert A. Figlin MD  Michael C. Fishbein MD  Robert M. Elashoff PhD  Steven M. Dubinett MD
Affiliation:1. Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California;2. Department of Medicine, Veterans Affairs North Texas Healthcare System, University of Texas Southwestern Medical Center, Dallas, Texas;3. Department of Biomathematics, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California;4. Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California;5. Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, Tennessee;6. Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars‐Sinai Medical Center, Los Angeles, California;7. Department of Pathology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California;8. Departments of Medicine and Pathology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California
Abstract:
Keywords:cyclooxygenase 2 (COX‐2)  erlotinib  celecoxib  non‐small cell lung cancer (NSCLC)  epidermal growth factor receptor (EGFR)  prostaglandin E2 (PGE2)
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号